Status and phase
Conditions
Treatments
About
The purpose of this research study is to determine if letrozole is effective at controlling the growth or spread of estrogen and/or progesterone receptor positive uterine leiomyosarcoma. This drug has been used in research studies for other cancers and is currently approved by the FDA for use in breast cancer. Because letrozole lowers hormone levels in the body, it may be helpful to control tumors that express hormone receptors ( ER/PR).
Full description
Participants will take letrozole orally once a day. During the research study the following tests and procedures will be performed: Visit 1 (Day 1): physical examination, vital signs and blood work Visit 2 (Day 43): physical examination, vital signs, blood work, CT or MRI scan Visit 3 (Day 85): physical examination, vital signs, blood work, CT or MRI scan Participants will remain on the study drug as long as they do not have any serious sife effect and their disease does not get worse
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
27 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal